Rocket


News + Filings
Transactions





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


SAPIRSTEIN JAMES Create: Alert

All | News | Filings
Date FiledTypeDescription
10/06/2023 4 SAPIRSTEIN JAMES (President and CEO) has filed a Form 4 on First Wave BioPharma, Inc.
Txns: Sold 2,764 shares @ $0.29, valued at $801.6
07/05/2023 4 SAPIRSTEIN JAMES (President and CEO) has filed a Form 4 on First Wave BioPharma, Inc.
Txns: Sold 3,349 shares @ $1.54, valued at $5.2k
06/01/2023 4 SAPIRSTEIN JAMES (Director) has filed a Form 4 on Blue Water Biotech, Inc.
Txns: Granted 6,360 shares @ $0
04/05/2023 4 SAPIRSTEIN JAMES (President and CEO) has filed a Form 4 on First Wave BioPharma, Inc.
Txns: Sold 3,347 shares @ $2.5, valued at $8.4k
04/04/2023 4 SAPIRSTEIN JAMES (Director) has filed a Form 4 on Enochian Biosciences Inc
Txns: Granted 64,655 options to buy @ $1.16, valued at $75k
01/17/2023 3 SAPIRSTEIN JAMES (Director) has filed a Form 3 on ZyVersa Therapeutics, Inc.
01/05/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
05/27/2022 4 SAPIRSTEIN JAMES (Director) has filed a Form 4 on Blue Water Vaccines Inc.
Txns: Granted 50,575 options @ $6.45, valued at $326.2k
02/23/2022 3 SAPIRSTEIN JAMES (Director) has filed a Form 3 on Blue Water Vaccines Inc.
01/03/2022 4 SAPIRSTEIN JAMES (PRES, CEO & CHAIRMAN OF BOARD) has filed a Form 4 on First Wave BioPharma, Inc.
Txns: Granted 150,000 options to buy @ $1.45, valued at $217.5k
07/02/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/23/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/11/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/15/2020 3 SAPIRSTEIN JAMES (Director) has filed a Form 3 on Blue Water Acquisition Corp.
09/10/2020 3 SAPIRSTEIN JAMES (Interim Chief Executive Office) has filed a Form 3 on MARIZYME INC
07/20/2020 4 SAPIRSTEIN JAMES (PRESIDENT AND CEO) has filed a Form 4 on AzurRx BioPharma, Inc.
Txns: Granted 1,200,000 options to buy @ $0.85, valued at $1M
Granted 13 convertible preferred @ $0
Granted 64,935 options to buy @ $0.85, valued at $55.2k
10/10/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/10/2019 3 Form 3 - Initial statement of beneficial ownership of securities:
08/26/2019 4 SAPIRSTEIN JAMES (Director) has filed a Form 4 on Enochian Biosciences Inc
Txns: Granted 9,173 options to buy @ $6.25, valued at $57.3k
09/27/2018 4 Form 4 - Statement of changes in beneficial ownership of securities:
09/04/2018 3 SAPIRSTEIN JAMES (Director) has filed a Form 3 on Enochian Biosciences Inc
01/05/2018 4 SAPIRSTEIN JAMES (CEO) has filed a Form 4 on ContraVir Pharmaceuticals, Inc.
Txns: Granted 322,092 shares @ $0
12/12/2017 4 SAPIRSTEIN JAMES (Director) has filed a Form 4 on RespireRx Pharmaceuticals Inc.
Txns: Acquired 38,114 options to buy @ $1.45, valued at $55.3k
07/07/2017 4 SAPIRSTEIN JAMES (CEO) has filed a Form 4 on ContraVir Pharmaceuticals, Inc.
Txns: Granted 141,061 shares @ $0
07/05/2017 4 Form 4 - Statement of changes in beneficial ownership of securities
03/07/2017 4 SAPIRSTEIN JAMES (CEO) has filed a Form 4 on ContraVir Pharmaceuticals, Inc.
02/15/2017 4 Form 4 - Statement of changes in beneficial ownership of securities
02/15/2017 3 Form 3 - Initial statement of beneficial ownership of securities
01/20/2017 4 Form 4 - Statement of changes in beneficial ownership of securities
10/31/2016 4 SAPIRSTEIN JAMES (CEO) has filed a Form 4 on ContraVir Pharmaceuticals, Inc.
06/14/2016 4 SAPIRSTEIN JAMES (CEO) has filed a Form 4 on ContraVir Pharmaceuticals, Inc.
Txns: Granted 500,000 options @ $0.99, valued at $495k
04/04/2016 4 Form 4 - Statement of changes in beneficial ownership of securities
02/18/2016 4 SAPIRSTEIN JAMES (CEO) has filed a Form 4 on ContraVir Pharmaceuticals, Inc.
11/09/2012 4 SAPIRSTEIN JAMES (CEO) has filed a Form 4 on Alliqua, Inc.
Txns: Granted 9,286,408 options to buy @ $0.1, valued at $928.6k
Granted 3,095,469 options to buy @ $0

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy